Haleon plc (LSE:HLN) has released its half-year 2026 results, publishing the full report through the London Stock Exchange and on its corporate website. The update provides investors with the group’s latest financial performance while reaffirming its commitment to maintaining transparent communication with shareholders and the market.
Interim Dividend Increased by 9%
The board approved an interim dividend of 2.4 pence per ordinary share for the first half of 2026, representing a 9% increase compared with the interim dividend paid a year earlier. The dividend is scheduled to be paid in mid-September to holders of ordinary shares and American Depositary Shares (ADSs).
Haleon also reaffirmed its policy of growing the ordinary dividend at least in line with adjusted earnings over time. In addition, the company announced that a recorded presentation of its results, followed by a question-and-answer session for analysts and investors, will be made available as part of its ongoing shareholder engagement programme.
Outlook Remains Positive
Management continues to target sustainable earnings growth, supported by improving profitability, healthy free cash flow generation and ongoing cost-efficiency initiatives. While short-term share price momentum has been relatively subdued and valuation metrics remain balanced, the company’s earnings outlook and commitment to increasing shareholder returns continue to support its long-term investment case.
About Haleon
Haleon plc (LSE:HLN) is a global consumer healthcare company focused on everyday health products across categories including oral care, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skincare.
Its portfolio includes globally recognised brands such as Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren, serving more than one billion consumers worldwide. Listed on both the London Stock Exchange and the New York Stock Exchange under the ticker HLN, Haleon continues to invest in research, innovation and product development to strengthen its leadership position in the global over-the-counter healthcare market.
Leave a Reply